{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:03:09Z","timestamp":1785006189773,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jcin.2022.05.050","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T17:38:24Z","timestamp":1658165904000},"page":"1466-1476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Impact of High Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8939-0222","authenticated-orcid":false,"given":"Yusuke","family":"Tomoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Soga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Imada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Hiramori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2022.05.050_bib1","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"suppl S","key":"10.1016\/j.jcin.2022.05.050_bib2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jcin.2022.05.050_bib3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2022.05.050_bib4","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2\u00b0P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2022.05.050_bib5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"Test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.05.050_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.amjcard.2020.03.043","article-title":"Lipoprotein (a): an update on a marker of residual risk and associated clinical manifestations","volume":"126","author":"Shah","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2022.05.050_bib7","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcin.2022.05.050_bib8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jcin.2021.07.042","article-title":"Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention","volume":"14","author":"Yoon","year":"2021","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2022.05.050_bib9","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2022.05.050_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.05.050_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2022.05.050_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jacc.2018.10.002","volume":"73","author":"Bailey","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.05.050_bib13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jacc.2014.12.036","article-title":"Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC)","volume":"65","author":"Patel","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.05.050_bib14","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","volume":"72","author":"Thygesen","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.05.050_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.jcin.2022.05.050_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-152-3-201002020-00019","article-title":"Reclassification calculations for persons with incomplete follow-up","volume":"152","author":"Steyerberg","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcin.2022.05.050_bib17","article-title":"Twenty-year predictors of peripheral arterial disease compared with coronary heart disease in the Scottish heart health extended cohort (SHHEC)","volume":"6","author":"Tunstall-Pedoe","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcin.2022.05.050_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1583\/09-2733.1","article-title":"Lipoprotein(a) and other serum lipid subfractions influencing primary patency after infrainguinal percutaneous transluminal angioplasty","volume":"16","author":"Giovanetti","year":"2009","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jcin.2022.05.050_bib19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/1526602817728068","article-title":"Usefulness of lipoprotein(a) for predicting clinical outcomes after endovascular therapy for aortoiliac atherosclerotic lesions","volume":"24","author":"Hishikari","year":"2017","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jcin.2022.05.050_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2021.11.019","article-title":"High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy","volume":"349","author":"Verwer","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jcin.2022.05.050_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/biom11020257","article-title":"Lipoprotein(a) and cardiovascular outcomes after revascularization of carotid and lower limbs arteries","volume":"11","author":"Ezhov","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jcin.2022.05.050_bib22","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2022.05.050_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.5551\/jat.56457","article-title":"Relationship between lipoprotein(a) and angiographic severity of femoropopliteal lesions","volume":"28","author":"Yanaka","year":"2021","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jcin.2022.05.050_bib24","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.8503012","article-title":"Proliferation of human smooth muscle cells promoted by lipoprotein(a)","volume":"260","author":"Grainger","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jcin.2022.05.050_bib25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.atherosclerosis.2011.02.004","article-title":"Carotid and femoral atherosclerotic plaques show different morphology","volume":"216","author":"Herisson","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jcin.2022.05.050_bib26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2022.05.050_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879822010913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879822010913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:16:30Z","timestamp":1761848190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879822010913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":27,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1936879822010913"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2022.05.050","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of High Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2022.05.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}